A novel surveillance protocol for stage I nonseminomatous germ cell testicular tumours

• DOI: 10.1046/j.1464-410x.2003.04270.x
• Publication Date: 2004-12-21T16:43:40Z
• Authors: N. Atsü; S. Eskiçorapçi; A. Üner; S. Ekici; Y. Güngen; I. Erkan; M.C. Uygur; H. Özen
• Keywords: Embryonal carcinoma; Lymphovascular invasion

To report the results of a novel surveillance policy for stage I nonseminomatous germ cell tumours (NSGCTs).Between 1978 and 2000, 132 patients (median age 28 years, range 16-52) who were regularly followed included in new policy. All pathology specimens studied retrospectively by same pathologist embryonal carcinoma, yolk sac tumour lymphovascular invasion components. A loose protocol was designed which computed tomography (CT) used only first year.The median (range) follow-up 38 (6-265) months; relapse rate 24% all occurred before 23 months, with 87% diagnosed within year. Platinum-based chemotherapy given to relapse, surgery after seven. Among risk factors, an carcinoma component significant predictor relapse. The overall survival 99%.The presence primary is factor determining present NSGCTs. no different from those reported retroperitoneal lymph node dissection chemotherapy. Decreasing frequency CT year totally eliminating it 1 reduces cost surveillance. possible compliance problems are also minimized, without changing survival. This NSGCT has reduced costs provided better quality life patients, jeopardizing final outcome.